Literature DB >> 16941480

A two-tier approach to mutation detection in the COL4A5 gene for Alport syndrome.

Kathy King1, Frances A Flinter, Peter M Green.   

Abstract

About 85% of Alport syndrome is an X-linked semi-dominant condition caused by mutations in the collagen gene, COL4A5. The large size and high GC content of this gene have presented diagnostic laboratories with problems in identifying mutations with greater than about a 50% success rate since the gene was first cloned 16 years ago. An RNA based approach is adopted here for a first pass mutation scanning coupled with more traditional exon-by-exon screening to increase the rate of mutation identification. Twenty-one mutations were identified in twenty-five patients with clear Alport syndrome including four gross deletions, two deep intronic mutations, three frameshifts, three splice site mutations, eight missense mutations and one inframe deletion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16941480     DOI: 10.1002/humu.9453

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  7 in total

1.  Recurrent deep intronic mutations in the SLC12A3 gene responsible for Gitelman's syndrome.

Authors:  Yi-Fen Lo; Kandai Nozu; Kazumoto Iijima; Takahiro Morishita; Che-Chung Huang; Sung-Sen Yang; Huey-Kang Sytwu; Yu-Wei Fang; Min-Hua Tseng; Shih-Hua Lin
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-04       Impact factor: 8.237

2.  Guidelines for Genetic Testing and Management of Alport Syndrome.

Authors:  Judy Savige; Beata S Lipska-Zietkiewicz; Elizabeth Watson; Jens Michael Hertz; Constantinos Deltas; Francesca Mari; Pascale Hilbert; Pavlina Plevova; Peter Byers; Agne Cerkauskaite; Martin Gregory; Rimante Cerkauskiene; Danica Galesic Ljubanovic; Francesca Becherucci; Carmela Errichiello; Laura Massella; Valeria Aiello; Rachel Lennon; Louise Hopkinson; Ania Koziell; Adrian Lungu; Hansjorg Martin Rothe; Julia Hoefele; Miriam Zacchia; Tamara Nikuseva Martic; Asheeta Gupta; Albertien van Eerde; Susie Gear; Samuela Landini; Viviana Palazzo; Laith Al-Rabadi; Kathleen Claes; Anniek Corveleyn; Evelien Van Hoof; Micheel van Geel; Maggie Williams; Emma Ashton; Hendica Belge; Elisabet Ars; Agnieszka Bierzynska; Concetta Gangemi; Alessandra Renieri; Helen Storey; Frances Flinter
Journal:  Clin J Am Soc Nephrol       Date:  2021-12-20       Impact factor: 8.237

3.  Prevalence Estimates of Predicted Pathogenic COL4A3-COL4A5 Variants in a Population Sequencing Database and Their Implications for Alport Syndrome.

Authors:  Joel Gibson; Rachel Fieldhouse; Melanie M Y Chan; Omid Sadeghi-Alavijeh; Leslie Burnett; Valerio Izzi; Anton V Persikov; Daniel P Gale; Helen Storey; Judy Savige
Journal:  J Am Soc Nephrol       Date:  2021-06-18       Impact factor: 14.978

4.  Pathogenicity of missense variants affecting the collagen IV α5 carboxy non-collagenous domain in X-linked Alport syndrome.

Authors:  Joel T Gibson; Omid Sadeghi-Alavijeh; Daniel P Gale; Hansjörg Rothe; Judy Savige
Journal:  Sci Rep       Date:  2022-07-04       Impact factor: 4.996

5.  Detection of large deletion mutations in the COL4A5 gene of female Alport syndrome patients.

Authors:  Kandai Nozu; Rafal Przybyslaw Krol; Yasufumi Ohtsuka; Koichi Nakanishi; Norishige Yoshikawa; Yoshimi Nozu; Hiroshi Kaito; Kyoko Kanda; Yuya Hashimura; Yuhei Hamasaki; Kazumoto Iijima; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2008-06-27       Impact factor: 3.714

Review 6.  Expert consensus guidelines for the genetic diagnosis of Alport syndrome.

Authors:  Judy Savige; Francesca Ariani; Francesca Mari; Mirella Bruttini; Alessandra Renieri; Oliver Gross; Constantinos Deltas; Frances Flinter; Jie Ding; Daniel P Gale; Mato Nagel; Michael Yau; Lev Shagam; Roser Torra; Elisabet Ars; Julia Hoefele; Guido Garosi; Helen Storey
Journal:  Pediatr Nephrol       Date:  2018-07-09       Impact factor: 3.714

7.  Genotype-phenotype correlation and prognostic impact in Chinese patients with Alport Syndrome.

Authors:  Shunlai Shang; Fei Peng; Tao Wang; Xiaoyuan Wu; Ping Li; Qinggang Li; Xiang M Chen
Journal:  Mol Genet Genomic Med       Date:  2019-05-29       Impact factor: 2.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.